Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -530.37x is 22% above its 4-year average of -681.76x, near the high end of its 4-year range (-2001.43x–-263.68x).
47.22% above its 12-month average of -1004.78x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -2001.43x.
INTEREST COVERAGE RATIO
-530.37x
INTEREST COVERAGE RATIO AVG TTM
-1004.78x
INTEREST COVERAGE RATIO AVG 3Y
-661.41x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+47.22%
CURRENT VS 3Y AVG
+19.81%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
-8219.53%
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$261.87M
Interest Coverage Ratio
-530.37x
TTM Avg
-1004.78x
3Y Avg
-661.41x
5Y Avg
N/A
Market Cap
$262.02M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.24M
Interest Coverage Ratio
-1805.60x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.19M
Interest Coverage Ratio
-9.79x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.32M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.93M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.73M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.50M
Interest Coverage Ratio
-360.54x
TTM Avg
23.12x
3Y Avg
23.12x
5Y Avg
1139.56x
Market Cap
$256.54M
Interest Coverage Ratio
N/A
TTM Avg
130.06x
3Y Avg
93.86x
5Y Avg
75.34x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $261.87M | -530.37x | -1004.78x | -661.41x | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $262.02M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | -1805.60x | N/A | N/A | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.19M | -9.79x | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $263.32M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.93M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $258.50M | -360.54x | 23.12x | 23.12x | 1139.56x |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.54M | N/A | 130.06x | 93.86x | 75.34x |
| Treace Medical Concepts, Inc. (TMCI)vs › | $267.60M | -10.18x | 0.19x | 0.19x | 0.19x |
Interest Coverage
-530.4x
Debt/Equity
0.03
Current Ratio
13.89
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -2001.43x |
| 2026-03-31 | -1313.71x |
| 2025-12-31 | -924.64x |
| 2025-09-30 | -264.00x |
| 2025-06-30 | -520.14x |
| 2025-03-31 | -845.13x |
| 2024-12-31 | -912.73x |
| 2024-09-30 | -901.23x |
| 2024-06-30 | -672.86x |
| 2024-03-31 | -629.49x |
| 2023-12-31 | -299.48x |
| 2023-09-30 | -389.87x |
| 2023-06-30 | -263.68x |
| 2023-03-31 | -385.80x |
| 2022-12-31 | -281.43x |
| 2022-09-30 | -602.83x |
| 2022-06-30 | -1701.22x |
